Welcome to our dedicated page for Hepion Pharmaceuticals news (Ticker: HEPA), a resource for investors and traders seeking the latest updates and insights on Hepion Pharmaceuticals stock.
Hepion Pharmaceuticals, Inc. (HEPA) generates news that reflects its transition from liver-focused drug development to diagnostic testing and its evolving capital markets profile. Company announcements describe Hepion as a clinical stage biopharmaceutical firm that had been developing rencofilstat, a cyclophilin inhibitor for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC) and other chronic liver diseases, and that is now concentrating on diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and HCC.
News items for HEPA commonly cover strategic shifts and partnerships, such as Hepion’s license agreement with New Day Diagnostics LLC to in-license diagnostic tests in these areas. Releases also discuss the status of its ASCEND-NASH Phase 2b clinical trial, including the decision to wind down and close the trial, and the subsequent sale of rencofilstat-related patent assets, knowhow and clinical data in exchange for a nominal amount and a contingent value right for stockholders.
Investors following HEPA will also find capital markets and listing updates in the news feed. Hepion has reported a reverse stock split intended to address Nasdaq’s minimum bid price requirement, a public offering of common stock and warrants, and later a delisting notification from Nasdaq citing continued listing standard deficiencies and concerns that the company was a public shell. Subsequent news confirms the suspension of trading on Nasdaq and the transition of HEPA shares to quotation on the OTCQB Venture Market.
The HEPA news stream further includes corporate transaction and governance developments, including the proposed but ultimately terminated merger with Pharma Two B Ltd., the effectiveness and later cancellation of a special stockholder meeting related to that transaction, and leadership changes such as the appointment of an interim Chief Executive Officer and the resignation of a chief financial officer and director. For readers tracking the company’s evolution toward precision diagnostics and its efforts to manage capital and strategic alternatives, the HEPA news page offers an organized view of these disclosures.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the Benzinga Biotech Small Cap Conference on March 25, 2021. CEO Dr. Robert Foster will provide a corporate overview at 9:45 a.m. Eastern Time, while Dr. Patrick Mayo will join a panel discussion on NASH treatments at 1:00 p.m. Eastern Time. The company's lead drug candidate, CRV431, targets non-alcoholic steatohepatitis (NASH) and demonstrates potential in reducing liver fibrosis and tumor burden in experimental models. Hepion also leverages its AI-POWR™ platform to optimize patient treatment outcomes.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the NASH-TAG 2021 Conference, taking place virtually from March 11-13, 2021. CEO Dr. Robert Foster will deliver an oral presentation on the positive top-line data from the Phase 2a ‘AMBITION’ clinical trial of CRV431, an innovative cyclophilin inhibitor. The presentation will highlight how the AI-POWR™ platform is utilized in optimizing study design for the upcoming Phase 2b trial. The presentation is scheduled for March 13, 2021, from 7:15 to 7:30 p.m. MT. More details can be found on the company's website.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced the closing of a public offering of 44,200,000 shares at $2.00 each, raising $88.4 million in gross proceeds. After expenses, the net proceeds amount to approximately $82.1 million. The funds will primarily support research and development activities along with general corporate needs. The offering was managed by ThinkEquity. Hepion's lead drug candidate, CRV431, targets liver diseases, particularly NASH, and shows promise for broader therapeutic applications.
Hepion Pharmaceuticals announced a public offering of 44,200,000 shares of common stock at $2.00 per share, raising gross proceeds of $88.4 million. The offering, managed by ThinkEquity, is set to close on February 18, 2021. The funds will support research and development activities, along with working capital. Hepion's lead drug candidate, CRV431, targets liver diseases, particularly non-alcoholic steatohepatitis (NASH). The company utilizes its AI platform, AI-POWR™, to enhance drug development and patient response identification.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced a proposed public offering of common stock, with all shares being sold by the Company. The offering is managed by ThinkEquity and is subject to market conditions. Proceeds will primarily be directed towards research and development, product development, and general corporate purposes. The securities are offered under a shelf registration statement previously filed with the SEC. The Company’s lead drug candidate, CRV431, targets liver disease.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced the appointment of Dr. Todd M. Hobbs as Chief Medical Officer, effective February 16, 2021. Dr. Hobbs, previously with Novo Nordisk for 16 years, will enhance Hepion's engagement with the FDA and key healthcare stakeholders. He is expected to play a significant role in advancing the clinical development of Hepion's lead drug candidate, CRV431, which targets non-alcoholic steatohepatitis (NASH) and liver disease. Hepion is utilizing its proprietary AI platform, AI-POWR™, to optimize treatment strategies for NASH patients.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced its participation in the BIO CEO & Investor Digital Conference from February 16 to 18, 2021. Their pre-recorded presentation will be available on demand for registered attendees and will also be accessible on their website for 30 days post-event. The company is focused on developing CRV431, a drug candidate targeting non-alcoholic steatohepatitis (NASH) and liver disease. Hepion is utilizing its proprietary AI platform, AI-POWR, to enhance drug development and identify optimal patient responses.
Hepion Pharmaceuticals (NASDAQ:HEPA), a clinical stage biopharmaceutical firm, announced its participation in two virtual investor conferences this January. The H.C. Wainwright BioConnect 2021 Conference will feature a pre-recorded presentation available on Hepion's website from January 11, 2021, for 90 days. Additionally, the Biotech Showcase 2021 Digital will provide on-demand content for registered participants. Hepion’s lead candidate, CRV431, targets non-alcoholic steatohepatitis (NASH) and is developed using their proprietary AI-POWR™ platform to enhance treatment outcomes.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced positive top-line results from the low-dose cohort of its Phase 2a 'AMBITION' clinical trial for CRV431, aimed at treating non-alcoholic steatohepatitis (NASH). The trial showed CRV431 to be generally safe and well tolerated, with significant reductions in key liver biomarkers, ALT and AST, observed over 28 days. The study continues with a higher dosage of 225 mg, with the completion of dosing expected in Q1 2021. The company will further analyze data to enhance the design of its Phase 2b trial, anticipated to start mid-2021.
Hepion Pharmaceuticals (NASDAQ:HEPA) announced that the independent Data Safety Monitoring Board (DSMB) has confirmed the safety and tolerability of CRV431 in its Phase 2a AMBITION trial for NASH patients. The DSMB approved the continuation of the trial after two interim analyses and recommended moving to the final dosing cohort of 225 mg, expected to be completed in early 2021. The AMBITION trial, the first placebo-controlled study for CRV431, targets patients with moderate-to-severe fibrosis, aiming to demonstrate the drug's efficacy in reducing liver fibrosis.